Key Points
Several pundits raised their price targets on the specialty healthcare company.
This was hardly a surprise, as they came on the heels of an excellent earnings report.
10 stocks we like better than GeneDx ›
GeneDx (NASDAQ: WGS) shareholders are having quite a spectacular week, and it’s not over yet. On Wednesday, the company’s stock soared again, notching a nearly 13% pop after the previous day’s 8%-plus increase. Still basking in the glow of a fine quarterly earnings report, GeneDx was bolstered by several new, bullish analyst updates.
The power of the pundit
GeneDx’s second-quarter earnings release showed not only a vast improvement in revenue and a flip into the black on the bottom line, but those fundamentals came in significantly higher than the consensus analyst estimates. As if that weren’t enough, management raised several key guidance items.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Image source: Getty Images.
It wasn’t hard to be optimistic about the company’s future in the wake of such results. Accordingly, no less than three analysts tracking GeneDx raised their price targets on its shares.
TD Cowen’s Dan Brennan was the most conservative of the trio, as he bumped his fair value assessment higher to $118 per share from his previous $110 while maintaining his buy recommendation. Wells Fargo pundit Brandon Couillard remains more cautious, as he kept his equal weight (read: hold) designation intact but lifted his price target to $95 per share from $78.
No denying the solid results
The most assertive raise of the three came from BTIG’s Mark Massaro, who now feels GeneDx is worth $125 per share, well up from the analyst’s preceding level of $100. Massaro remains bullish on the company, since he maintained his existing buy recommendation.
According to reports, the BTIG pundit wrote in his new take on the company that not only was its second quarter impressive, but it can also benefit from several factors including lower test denial rates from healthcare providers.
Should you invest $1,000 in GeneDx right now?
Before you buy stock in GeneDx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $630,291!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,075,791!*
Now, it’s worth noting Stock Advisor’s total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
